{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:56:07Z","timestamp":1794945367292,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54-CA196519-04"],"award-info":[{"award-number":["U54-CA196519-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K12-HD000850"],"award-info":[{"award-number":["K12-HD000850"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1038\/s41591-020-01193-6","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T16:03:12Z","timestamp":1610553792000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Cabozantinib for neurofibromatosis type 1\u2013related plexiform neurofibromas: a phase 2 trial"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3408-3839","authenticated-orcid":false,"given":"Michael J.","family":"Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie-Schin","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Angus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole J.","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Gutmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tena","family":"Rosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent A.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C.","family":"Widemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbi E.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waylan K.","family":"Bessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Mund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijeh","family":"Bijangi-Vishehsaraei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coretta Thomas","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Korf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Neurofibromatosis Clinical Trials Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie-Schin","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Wade","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"1193_CR1","unstructured":"PhRMA. A Decade of Innovation In Rare Diseases. http:\/\/phrma-docs.phrma.org\/sites\/default\/files\/pdf\/PhRMA-Decade-of-Innovation-Rare-Diseases.pdf (2015)."},{"key":"1193_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","volume":"89","author":"JM Friedman","year":"1999","unstructured":"Friedman, J. M. Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 89, 1\u20136 (1999).","journal-title":"Am. J. Med. Genet."},{"key":"1193_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.2134734","volume":"249","author":"MR Wallace","year":"1990","unstructured":"Wallace, M. R. et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249, 181\u2013186 (1990).","journal-title":"Science"},{"key":"1193_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","volume":"62","author":"D Viskochil","year":"1990","unstructured":"Viskochil, D. et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187\u2013192 (1990).","journal-title":"Cell"},{"key":"1193_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","volume":"63","author":"R Ballester","year":"1990","unstructured":"Ballester, R. et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63, 851\u2013859 (1990).","journal-title":"Cell"},{"key":"1193_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1517\/13543784.2013.772979","volume":"22","author":"DH Gutmann","year":"2013","unstructured":"Gutmann, D. H., Blakeley, J. O., Korf, B. R. & Packer, R. J. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin. Investig. Drugs 22, 443\u2013462 (2013).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1193_CR7","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-17-1789","volume":"77","author":"O Maertens","year":"2017","unstructured":"Maertens, O. et al. A collaborative model for accelerating the discovery and translation of cancer therapies. Cancer Res. 77, 5706\u20135711 (2017).","journal-title":"Cancer Res."},{"key":"1193_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/0883073817739196","volume":"33","author":"RJ Packer","year":"2018","unstructured":"Packer, R. J., Fisher, M. J., Cutter, G., Cole-Plourde, K. & Korf, B. R. Neurofibromatosis Cinical Trial Consortium. J. Child Neurol. 33, 82\u201391 (2018).","journal-title":"J. Child Neurol."},{"key":"1193_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1212\/01.wnl.0000435743.49414.b6","volume":"81","author":"SR Plotkin","year":"2013","unstructured":"Plotkin, S. R. et al. Achieving consensus for clinical trials: the REiNS International Collaboration. Neurology 81, S1\u2013S5 (2013).","journal-title":"Neurology"},{"key":"1193_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1146\/annurev-pathol-011811-132441","volume":"7","author":"K Staser","year":"2012","unstructured":"Staser, K., Yang, F. C. & Clapp, D. W. Pathogenesis of plexiform neurofibroma: tumor-stromal\/hematopoietic interactions in tumor progression. Annu. Rev. Pathol. 7, 469\u2013495 (2012).","journal-title":"Annu. Rev. Pathol."},{"key":"1193_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","volume":"115","author":"RE Ferner","year":"2013","unstructured":"Ferner, R. E. & Gutmann, D. H. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb. Clin. Neurol. 115, 939\u2013955 (2013).","journal-title":"Handb. Clin. Neurol."},{"key":"1193_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1215\/15228517-2008-011","volume":"10","author":"VF Mautner","year":"2008","unstructured":"Mautner, V. F. et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro. Oncol. 10, 593\u2013598 (2008).","journal-title":"Neuro. Oncol."},{"key":"1193_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","volume":"20","author":"AM Gross","year":"2018","unstructured":"Gross, A. M. et al. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro. Oncol. 20, 1643\u20131651 (2018).","journal-title":"Neuro. Oncol."},{"key":"1193_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DG Evans","year":"2002","unstructured":"Evans, D. G. et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39, 311\u2013314 (2002).","journal-title":"J. Med. Genet."},{"key":"1193_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner, N. & Miller, S. J. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer 15, 290\u2013301 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1193_CR16","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijrobp.2008.03.073","volume":"73","author":"S Wentworth","year":"2009","unstructured":"Wentworth, S. et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int. J. Radiat. Oncol. Biol. Phys. 73, 208\u2013213 (2009).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1193_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0360-3016(81)90102-4","volume":"7","author":"HM Greenberg","year":"1981","unstructured":"Greenberg, H. M. et al. Radiation therapy in the treatment of aggressive fibromatoses. Int. J. Radiat. Oncol. Biol. Phys. 7, 305\u2013310 (1981).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1193_CR18","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N. Engl. J. Med. 375, 2550\u20132560 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1193_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross, A. M. et al. Selumetinib in children with inoperable plexiform neurofibromas. N. Engl. J. Med. 382, 1430\u20131442 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1193_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cell.2008.08.041","volume":"135","author":"FC Yang","year":"2008","unstructured":"Yang, F. C. et al. Nf1-dependent tumors require a microenvironment containing Nf1+\/\u2212 and c-Kit-dependent bone marrow. Cell 135, 437\u2013448 (2008).","journal-title":"Cell"},{"key":"1193_CR21","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/hmg\/ddl108","volume":"15","author":"AM Munchhof","year":"2006","unstructured":"Munchhof, A. M. et al. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Hum. Mol. Genet. 15, 1858\u20131869 (2006).","journal-title":"Hum. Mol. Genet."},{"key":"1193_CR22","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","volume":"13","author":"KA Robertson","year":"2012","unstructured":"Robertson, K. A. et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 13, 1218\u20131224 (2012).","journal-title":"Lancet Oncol."},{"key":"1193_CR23","doi-asserted-by":"crossref","unstructured":"Rhodes, S. D. et al. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum. Mol. Genet. 28, 2752\u20132762 (2019).","DOI":"10.1093\/hmg\/ddz095"},{"key":"1193_CR24","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.2217\/fon.13.128","volume":"9","author":"D Viola","year":"2013","unstructured":"Viola, D., Cappagli, V. & Elisei, R. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol. 9, 1083\u20131092 (2013).","journal-title":"Future Oncol."},{"key":"1193_CR25","doi-asserted-by":"crossref","unstructured":"Cabozantinib approved for renal cell carcinoma. Cancer Discov. 6, OF3 (2016).","DOI":"10.1158\/2159-8290.CD-NB2016-057"},{"key":"1193_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54\u201363 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1193_CR27","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes, F. M. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 10, 2298\u20132308 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"1193_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/978-3-319-91442-8_5","volume":"211","author":"C Grullich","year":"2018","unstructured":"Grullich, C. Cabozantinib: multi-kinase inhibitor of MET, AXL, RET, and VEGFR2. Recent Results Cancer Res. 211, 67\u201375 (2018).","journal-title":"Recent Results Cancer Res"},{"key":"1193_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/CAD.0000000000000366","volume":"27","author":"L Nguyen","year":"2016","unstructured":"Nguyen, L., Benrimoh, N., Xie, Y., Offman, E. & Lacy, S. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs 27, 669\u2013678 (2016).","journal-title":"Anticancer Drugs"},{"key":"1193_CR30","doi-asserted-by":"publisher","first-page":"e28372","DOI":"10.1002\/pbc.28372","volume":"67","author":"AE Armstrong","year":"2020","unstructured":"Armstrong, A. E. et al. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1. Pediatr. Blood Cancer 67, e28372 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"1193_CR31","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035\u20131044 (2007).","journal-title":"Nat. Biotechnol."},{"key":"1193_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","volume":"149","author":"JS Duncan","year":"2012","unstructured":"Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307\u2013321 (2012).","journal-title":"Cell"},{"key":"1193_CR33","unstructured":"Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, eaan4368 (2017)."},{"key":"1193_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-017-0579-4","volume":"19","author":"M Schoumacher","year":"2017","unstructured":"Schoumacher, M. & Burbridge, M. Key roles of AXL and MER receptor tyrosine kinases in resistance to multiple anticancer therapies. Curr. Oncol. Rep. 19, 19 (2017).","journal-title":"Curr. Oncol. Rep."},{"key":"1193_CR35","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi, E. et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81, S33\u2013S40 (2013).","journal-title":"Neurology"},{"key":"1193_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","volume":"88","author":"JT Farrar","year":"2000","unstructured":"Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L. & Strom, B. L. Defining the clinically important difference in pain outcome measures. Pain 88, 287\u2013294 (2000).","journal-title":"Pain"},{"key":"1193_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11060-017-2723-2","volume":"137","author":"K Nutakki","year":"2018","unstructured":"Nutakki, K., Varni, J. W. & Swigonski, N. L. PedsQL Neurofibromatosis Type 1 Module for children, adolescents and young adults: feasibility, reliability, and validity. J. Neurooncol. 137, 337\u2013347 (2018).","journal-title":"J. Neurooncol."},{"key":"1193_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/cyto.b.20602","volume":"80","author":"KR Pradhan","year":"2011","unstructured":"Pradhan, K. R. et al. Polychromatic flow cytometry identifies novel subsets of circulating cells with angiogenic potential in pediatric solid tumors. Cytometry B Clin. Cytom. 80, 335\u2013338 (2011).","journal-title":"Cytometry B Clin. Cytom."},{"key":"1193_CR39","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen, W. J. et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 123, 340\u2013347 (2013).","journal-title":"J. Clin. Invest."},{"key":"1193_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pbc.23015","volume":"58","author":"J Wu","year":"2012","unstructured":"Wu, J. et al. Preclincial testing of sorafenib and RAD001 in the Nffl\/fl\u2009;\u2009DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr. Blood Cancer 58, 173\u2013180 (2012).","journal-title":"Pediatr. Blood Cancer"},{"key":"1193_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/pbc.25763","volume":"63","author":"MJ Ferguson","year":"2016","unstructured":"Ferguson, M. J. et al. Preclinical evidence for the use of sunitinib malate in the treatment of plexiform neurofibromas. Pediatr. Blood Cancer 63, 206\u2013213 (2016).","journal-title":"Pediatr. Blood Cancer"},{"key":"1193_CR42","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/bjc.2016.428","volume":"116","author":"CM Gay","year":"2017","unstructured":"Gay, C. M., Balaji, K. & Byers, L. A. Giving AXL the axe: targeting AXL in human malignancy. Br. J. Cancer 116, 415\u2013423 (2017).","journal-title":"Br. J. Cancer"},{"key":"1193_CR43","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/neuonc\/nou235","volume":"17","author":"B Weiss","year":"2015","unstructured":"Weiss, B. et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro. Oncol. 17, 596\u2013603 (2015).","journal-title":"Neuro. Oncol."},{"key":"1193_CR44","first-page":"289","volume":"19","author":"RI Jakacki","year":"2017","unstructured":"Jakacki, R. I. et al. Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro. Oncol. 19, 289\u2013297 (2017).","journal-title":"Neuro. Oncol."},{"key":"1193_CR45","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","volume":"68","author":"E Dombi","year":"2007","unstructured":"Dombi, E. et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology 68, 643\u2013647 (2007).","journal-title":"Neurology"},{"key":"1193_CR46","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1172\/JCI85183","volume":"126","author":"R Lock","year":"2016","unstructured":"Lock, R. et al. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J. Clin. Invest. 126, 2181\u20132190 (2016).","journal-title":"J. Clin. Invest."},{"key":"1193_CR47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri, T. K. et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J. Clin. Oncol. 35, 591\u2013597 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1193_CR48","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1200\/JCO.2017.73.0226","volume":"35","author":"ME Cabanillas","year":"2017","unstructured":"Cabanillas, M. E. et al. Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial. J. Clin. Oncol. 35, 3315\u20133321 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1193_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","volume":"22","author":"SM Tolaney","year":"2017","unstructured":"Tolaney, S. M. et al. Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients. Oncologist 22, 25\u201332 (2017).","journal-title":"Oncologist"},{"key":"1193_CR50","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1089\/thy.2013.0621","volume":"24","author":"S Yavuz","year":"2014","unstructured":"Yavuz, S. et al. Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma. Thyroid 24, 1223\u20131231 (2014).","journal-title":"Thyroid"},{"key":"1193_CR51","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/pbc.25546","volume":"62","author":"E Jousma","year":"2015","unstructured":"Jousma, E. et al. Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1. Pediatr. Blood Cancer 62, 1709\u20131716 (2015).","journal-title":"Pediatr. Blood Cancer"},{"key":"1193_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0747-y","volume":"14","author":"R Leibowitz-Amit","year":"2016","unstructured":"Leibowitz-Amit, R. et al. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. J. Transl. Med. 14, 12 (2016).","journal-title":"J. Transl. Med."},{"key":"1193_CR53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.compmedimag.2004.03.002","volume":"28","author":"J Solomon","year":"2004","unstructured":"Solomon, J., Warren, K., Dombi, E., Patronas, N. & Widemann, B. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput. Med. Imaging Graph. 28, 257\u2013265 (2004).","journal-title":"Comput. Med. Imaging Graph."},{"key":"1193_CR54","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/ard.37.4.378","volume":"37","author":"WW Downie","year":"1978","unstructured":"Downie, W. W. et al. Studies with pain rating scales. Ann. Rheum. Dis. 37, 378\u2013381 (1978).","journal-title":"Ann. Rheum. Dis."},{"key":"1193_CR55","first-page":"129","volume":"23","author":"CS Cleeland","year":"1994","unstructured":"Cleeland, C. S. & Ryan, K. M. Pain assessment: global use of the Brief Pain Inventory. Ann. Acad. Med. Singap. 23, 129\u2013138 (1994).","journal-title":"Ann. Acad. Med. Singap."},{"key":"1193_CR56","first-page":"9.33.1","volume":"52","author":"ML Estes","year":"2010","unstructured":"Estes, M. L., Mund, J. A., Ingram, D. A. & Case, J. Identification of endothelial cells and progenitor cell subsets in human peripheral blood. Curr. Protoc. Cytom. 52, 9.33.1\u20139.33.11 (2010).","journal-title":"Curr. Protoc. Cytom."},{"key":"1193_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 10, 1\u201310 (1989).","journal-title":"Control. Clin. Trials"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-01193-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-01193-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-01193-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T17:20:26Z","timestamp":1674840026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-020-01193-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1038\/s41591-020-01193-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"19 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: C.-S.S. is currently employed at Merck Research Laboratories (MRL) within Merck and Co. in Late Stage Oncology Clinical Development and is a consultant for the Selumetinib NF program at MRL. P.L.W. has holdings in Bristol-Myers Squibb under the amount allowable by the NIH. The remaining authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}